Curated News
By: NewsRamp Editorial Staff
April 14, 2026

Aclarion Wins Top AI Award for Chronic Back Pain Diagnostic Breakthrough

Discuss on LinkedIn Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Aclarion's award-winning Nociscan AI platform offers a competitive edge by targeting the costly chronic low back pain market with a 97% surgical success rate.
  • Nociscan uses MR spectroscopy to extract chemical biomarkers, which proprietary cloud-based algorithms analyze to classify discs as painful or non-painful for physicians.
  • This technology helps millions suffering from chronic low back pain by providing objective data to improve treatment planning and reduce healthcare costs.
  • Aclarion's Nociscan is the first evidence-supported SaaS platform that noninvasively distinguishes painful discs using biochemical biomarkers from MRI data.

Impact - Why it Matters

This development matters because chronic low back pain represents one of the most significant healthcare burdens globally, affecting millions of people and costing healthcare systems billions annually in treatment expenses and lost productivity. Traditional diagnostic methods for discogenic pain often rely on subjective patient reports and imaging that may not accurately identify pain sources, leading to ineffective treatments, unnecessary procedures, and prolonged patient suffering. Aclarion's Nociscan technology addresses this critical gap by providing objective, biochemical data that helps physicians pinpoint the exact source of pain with greater accuracy. For patients, this means more targeted treatments, potentially higher success rates for interventions like surgery (97% success rate when Nociscan-positive discs are treated), and reduced trial-and-error approaches that delay relief. For healthcare systems, it offers the potential to reduce costs associated with ineffective treatments and repeated procedures while improving patient outcomes. The cloud-based nature of the platform also makes this advanced diagnostic capability accessible without major infrastructure investments, potentially democratizing access to precision spine care across different healthcare settings.

Summary

Aclarion, Inc., a commercial-stage healthcare technology company, has achieved significant recognition for its innovative approach to chronic low back pain diagnosis. The company recently received a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category, following its earlier selection as a 2025 Digital Health Awards at HLTH winner. These accolades validate Aclarion's mission to bring objective, MR spectroscopy-based biomarker analysis into routine clinical decision-making through its flagship platform, Nociscan. This cloud-based SaaS solution uses proprietary augmented intelligence algorithms to analyze chemical biomarkers within intervertebral discs, helping physicians distinguish between painful and non-painful discs in the lumbar spine. The technology represents a breakthrough in addressing one of healthcare's most pervasive and costly challenges, with chronic low back pain affecting approximately 266 million people worldwide suffering from degenerative spine disease.

The core innovation lies in Nociscan's ability to provide physicians with objective biochemical data that complements traditional imaging and clinical evaluation. As CEO Brent Ness emphasized, this technology has the potential to fundamentally improve how discogenic pain is evaluated and treated. The platform operates through a cloud-based analytics system that can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure, making it scalable and accessible. Clinical data demonstrates impressive results, with a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. This evidence-supported approach marks a significant advancement in precision medicine for spine care, offering physicians more reliable tools for treatment planning.

Aclarion's growing recognition reflects the accelerating momentum behind their technology and its potential impact on the healthcare industry. The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools for evaluating chronic low back pain. For those interested in learning more about this groundbreaking technology, additional information is available through the company's Latest News page and their contact email. The Pinnacle Awards 2026 AI Winners document provides further details about the award recognition, while the original press release distributed through PRISM MediaWire offers comprehensive coverage of this development in medical technology innovation.

Source Statement

This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, Aclarion Wins Top AI Award for Chronic Back Pain Diagnostic Breakthrough

blockchain registration record for this content.